Maybe we could do it...
$10 Million Archon X PRIZE for Genomics Challenges Private Companies to Map 100 Human Genomes in 10 Days
Washington D.C. (October 4, 2006) — The X PRIZE Foundation announced
today the $10 million Archon X PRIZE for Genomics — A multi-million
dollar incentive to create technology that can successfully map 100
human genomes in 10 days. The prize is designed to usher in a new era
of personalized preventative medicine and stimulate new avenues of
research and development of medical sciences.
Rapid genome sequencing is widely regarded as the next great
frontier for science and will eventually allow doctors to determine an
individuals’ susceptibility to disease and even the genetic links to
cancer. Mapping your genetic code is like taking an X-Ray allowing
doctors to see inside your genetic past and eventually help determine
your genetic future.
Only after we have access to affordable and fast genome sequencing
will we be able to take advantage of the countless benefits. This
technology helps us refine and perfect our knowledge and practice of
preventive medical treatments and procedures. Preventing disease is the
next best thing to curing disease.
This is the second major prize from the X PRIZE Foundation. In 1996,
the Foundation offered the Ansari X PRIZE for Private Spaceflight.
Until now, The X PRIZE Foundation has been considered part of the
nascent private spaceflight industry. Exactly two years ago today the
$10 Ansari X PRIZE for Private Spaceflight made world headlines when it
was won by Mojave Aerospace Ventures, a team led by famed aircraft
designer Burt Rutan and Microsoft co-founder Paul Allen. Their winning
entry, SpaceShipOne, is now the prototype for a new class of
sub-orbital spaceflight.
"The X PRIZE Foundation has created a unique philanthropic prize
model designed to stimulate research and accelerate development of
radical breakthroughs that will benefit humanity," explains Dr. Peter
H. Diamandis, Founder and Chairman of the X PRIZE Foundation. "The
Archon X PRIZE for Genomics will revolutionize personalized medicine
and custom medical treatment, forever changing the face of medical
research and making genome sequencing affordable and available in every
hospital and medical care facility in the world."
Three teams have already signed up for the competition. VisiGen
Biotechnologies, Inc. is based out of Houston, TX and is led by Susan
Hardin Ph.D., 454 Life Sciences is a Connecticut based company headed
up by Christopher McLeod and the third team, which is made up of the
Westheimer Institute for Science and Technology, the Foundation for
Applied Molecular Evolution, and Firebird Biomolecular Sciences LLC.
They make their home in Gainesville, FL and Steve Benner is the team
leader. Many other companies have inquired and more teams are expected
to register soon.